Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01922037
Recruitment Status : Completed
First Posted : August 14, 2013
Results First Posted : December 11, 2017
Last Update Posted : December 11, 2017
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.

Condition or disease Intervention/treatment Phase
Asthma Drug: Omalizumab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 806 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab
Actual Study Start Date : June 19, 2013
Actual Primary Completion Date : March 31, 2016
Actual Study Completion Date : March 31, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Omalizumab

Arm Intervention/treatment
Experimental: Participants With Allergic Asthma
Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
Drug: Omalizumab
Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
Other Name: Xolair




Primary Outcome Measures :
  1. Total Number of Asthma Exacerbations During Months 1-12 [ Time Frame: Months 1-12 ]
    An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for >/= 3 days.


Secondary Outcome Measures :
  1. Total Number of Asthma Exacerbations During Months 1-6 [ Time Frame: Months 1-6 ]
    An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for >/=3 days.

  2. Total Number of Asthma Exacerbations During Months 7-12 [ Time Frame: Months 7-12 ]
    An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for >/= 3 days.

  3. Total Number of Asthma-Related Hospital Admissions During Months 1-12 [ Time Frame: Months 1-12 ]
  4. Total Number of Asthma-Related Hospital Admissions During Months 1-6 [ Time Frame: Months 1-6 ]
  5. Total Number of Asthma-Related Hospital Admissions During Months 7-12 [ Time Frame: Months 7-12 ]
  6. Total Number of Asthma-Related ER Visits During Months 1-12 [ Time Frame: Months 1-12 ]
  7. Total Number of Asthma-Related Emergency Room (ER) Visits During Months 1-6 [ Time Frame: Months 1-6 ]
  8. Total Number of Asthma-Related ER Visits During Months 7-12 [ Time Frame: Months 7-12 ]
  9. Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-12 [ Time Frame: Months 1-12 ]
  10. Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 1-6 [ Time Frame: Months 1-6 ]
  11. Total Number of Asthma-Related Unscheduled Physician's Office Visits During Months 7-12 [ Time Frame: Months 7-12 ]
  12. Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-12 [ Time Frame: Months 1-12 ]
  13. Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 1-6 [ Time Frame: Months 1-6 ]
  14. Total Number of Asthma-Related Telephone Calls to Healthcare Providers During Months 7-12 [ Time Frame: Months 7-12 ]
  15. Percentage of Participants by Number of Asthma Exacerbations [ Time Frame: Months 1-12 ]
    Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, >/=4) was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for >/= 3 days.

  16. Percentage of Participants by Number of Asthma Exacerbations Requiring Treatment With Systemic Steroids [ Time Frame: Months 1-12 ]
    Percentage of participants by number of asthma exacerbations (0, 1, 2, 3, >/=4) requiring treatment with systemic steroids was reported. An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for >/= 3 days.

  17. Change From Baseline in Raw Forced Expiratory Volume in One Second (FEV1) [ Time Frame: Baseline, Month 6, end of study (EOS)/early termination (ET) (up to Month 12) ]
    FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. Pre-bronchodilator FEV1 and post-bronchodilator FEV1 are reported for each timepoint. FEV1 was measured using spirometry.

  18. Change From Baseline in Raw Forced Vital Capacity (FVC) [ Time Frame: Baseline, Month 6, EOS/ET (up to Month 12) ]
    FVC was defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pre-bronchodilator FVC and post-bronchodilator FVC are reported for each timepoint. FVC was measured using spirometry.

  19. Change From Baseline in Raw Forced Expiratory Flow at 25-75 Percent (%) of Pulmonary Volume (FEF25%-75%) [ Time Frame: Baseline, Month 6, EOS/ET (up to Month 12) ]
    FEF25%-75% was defined as the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Pre-bronchodilator FEF25%-75% and post-bronchodilator FEF25%-75% are reported for each timepoint. FEF25%-75% was measured using spirometry.

  20. Change From Baseline in Percentage Predicted FEV1 (ppFEV1) [ Time Frame: Baseline, Month 6, EOS/ET (up to Month 12) ]
    FEV1 is the volume of air that can be forced out in one second after taking a deep breath, as measured using spirometry. Hankinson and Wang standards were used to calculate ppFEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. ppFEV1= 100 multiplied by (*) FEV1 (in liters [L]) divided by (/) predicted FEV1 (in L). Pre-bronchodilator ppFEV1 and post-bronchodilator ppFEV1 are reported for each timepoint.

  21. Percentage of Participants With Prior Asthma Medications by Category or Class of Medications [ Time Frame: Baseline ]
    Prior asthma medications were defined as all medications used for asthma prior to the study (initiated within 90 days of baseline) and were assessed retrospectively at baseline. Participants received prior asthma medications of following categories or classes: short acting beta agonist (SABA), combination inhaled corticosteroids/long acting beta agonist (ICS/LABA), leukotriene receptor antagonist (LTRA), inhaled corticosteroids (ICS), oral/parenteral (systemic) corticosteroids, anticholinergic, long acting beta agonist (LABA), and other medication.

  22. Percentage of Participants With Concomitant and Ongoing Asthma Medications by Category or Class of Medications [ Time Frame: Baseline until EOS/ET (up to Month 12) ]
    Concomitant and ongoing asthma medications were defined as all medications used for asthma which began on or after the participant's study start, as well as those ongoing at the beginning of the study. Participants received following categories or classes of concomitant and ongoing asthma medications: SABA, combination ICS/LABA, LTRA, oral/parenteral (systemic) corticosteroids, ICS, anticholinergic, LABA, and other medication.

  23. Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) Overall Score [ Time Frame: Baseline, Month 6, EOS/ET (up to Month 12) ]
    AQLQ +12 is a 32-item disease specific questionnaire designed to assess the participants' asthma-specific health-related quality of life (QOL). The questionnaire contains four domains: activity limitations (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). All items are scored on a 7-point likert scale. All item scores are averaged to produce one overall QOL score. Overall score ranges from 1 (total impairment) to 7 (no impairment), with higher scores indicating better QOL. A positive change from baseline indicated improved QOL.

  24. Change From Baseline in Asthma Control Test (ACT) Overall Score [ Time Frame: Baseline, Months 3, 6, 9, 12 ]
    Multidimensional factors associated with asthma control from the participant's perspective were assessed using the ACT questionnaire. The ACT is a validated, five-item patient-reported outcome (PRO) questionnaire that measures the impact of asthma on home and work activities, shortness of breath, symptoms, rescue medication usage, and overall asthma control. All items are scored on a 5-point likert scale (1 to 5). All item scores are added together to calculate a total score. Total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. A positive change from baseline indicated improvement.

  25. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score [ Time Frame: Baseline, Month 6, EOS/ET (up to Month 12) ]
    WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity. A negative change in score indicated improvement and a positive change indicated impairment.

  26. Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using Global Evaluation of Treatment Effectiveness (GETE) by Inversigator [ Time Frame: EOS/ET (up to Month 12) ]
    Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by investigator, is reported.

  27. Percentage of Participants Who Showed an Improvement in Asthma Symptoms Due to the Medication, Assessed Using GETE by Participant [ Time Frame: EOS/ET (up to Month 12) ]
    Response to treatment was assessed using the GETE. The GETE is a validated instrument that measures the overall impression of the effect of the study medication on typical asthma symptoms. The evaluation was performed using the 5-point scale. The GETE scale ranges were as follows: 1=excellent, 2=good, 3=moderate, 4=poor, 5= worsening. A good or excellent response on the 5 point scale indicated that a participant had responded to treatment. Percentage of participants who showed an improvement (GETE scale score of 1 or 2) in asthma symptoms, as assessed by participant, is reported.

  28. Change From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Quality of Life Score [ Time Frame: Baseline, EOS/ET (up to Month 12) ]
    The MiniRQLQ is a shorter version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) instrument. The MiniRQLQ is a validated quality of life questionnaire to measure the functional impairments that are most troublesome to adult participants with either seasonal or perennial rhinoconjunctivitis of either allergic or non-allergic origin. The miniRQLQ contains 14 items; each item scored on a 7-point scale ranging from 0 [not impaired at all] to 6 [severely impaired]). The overall quality of life score is the average of the all item scores and ranges from 0 (not impaired at all) to 6 (severely impaired), with higher scores indicating more impairment. A negative change in score indicated improvement and a positive change indicated impairment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants identified by the investigator as a candidate for treatment for asthma with omalizumab
  • Confirmation of access to omalizumab through insurance or other source of funding

Exclusion Criteria:

  • Enrollment in any other concurrent clinical trial or observational study
  • Participants for whom omalizumab treatment is contraindicated
  • Participants who had a prior allergic reaction to omalizumab or its excipients
  • Participants treated with omalizumab within the previous year
  • Participants who received an experimental drug as part of another study within 3 months of enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922037


Locations
Show Show 145 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01922037    
Other Study ID Numbers: ML28528
First Posted: August 14, 2013    Key Record Dates
Results First Posted: December 11, 2017
Last Update Posted: December 11, 2017
Last Verified: November 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Omalizumab
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents